Kiin Bio

Kiin Bio, located in the UK, specializes in AI-powered drug discovery solutions, integrating over 100 tools into an intelligent workflow to enhance research efficiency and streamline drug development processes. Kiin Bio is a biotechnology company focused on automating drug discovery through an innovative platform. Founded in 2024 in London, UK, the company has established itself with 1 deal to date. In June 2025, Kiin Bio raised EUR 1.

9 million in pre-seed funding led by new investor b2venture, with participation from other new investors Heartfelt Capital Management and rule30. Individual investors also participated in the round. The company's founder has not been publicly detailed but is recognized for advancing biotechnology initiatives. Kiin Bio offers an AI-driven drug discovery platform that incorporates over 100 specialized tools into a coherent workflow.

This platform facilitates the design of experiments, complex data analysis, and improves research efficiency via AI-driven Virtual Scientists, aiding in the drug discovery and development process. Kiin Bio caters to a global client base, including researchers and biomedical institutions, particularly in North America, Europe, and Asia, targeting organizations seeking expedited research timelines and enhanced drug discovery methods. Kiin Bio's revenue model is based on subscription services granting access to its integrated drug discovery platform. Clients, primarily B2B pharmaceutical companies and research institutions, enter partnerships for annual or monthly subscriptions, which allow ongoing access to the platform's capabilities.

Although specific pricing details are not disclosed, this model fosters long-term relationships with clients, ensuring steady revenue streams as they depend on Kiin Bio for critical research and data analysis. In June 2025, Kiin Bio raised EUR 1. 9 million in pre-seed funding led by new investor b2venture, with participation from other new investors Heartfelt Capital Management and rule30. Individual investors also participated in the round.

The company will use the June 2025 funding to develop AI software for automating drug discovery processes.